• Overview
    • Why Invest
    • Press Releases & News
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • SEC Filings
      • Historical Financial Tables
    • Governance
      • Executive Leadership Team
      • Board of Directors
      • Committee Composition
      • Governance Documents
      • Contact the Board
    • Resources
      • Supplemental Information
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
Skip to main content
Evolus, Inc Evolus, Inc

Supplemental Information

  • Overview
    • Why Invest
    • Press Releases & News
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • SEC Filings
      • Historical Financial Tables
    • Governance
      • Executive Leadership Team
      • Board of Directors
      • Committee Composition
      • Governance Documents
      • Contact the Board
    • Resources
      • Supplemental Information
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
Download item year list
Thumb Download Description
(opens in new window)
Camelback Dermatology (opens in new window)
179.12 MB
(opens in new window)
Totality Medispa (opens in new window)
150.88 MB
(opens in new window)
Advanced Facial Surgery (opens in new window)
179.03 MB

Clinical Publications

Download item year list
Download Description
PrabotulinumtoxinA Versus OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines (Aesthetics Surgery Journal, 2022) (opens in new window)
PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines (Dermatologic Surgery, 2022) (opens in new window)
1/2 Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients (Aesthetic Surgery Journal, 2021) (opens in new window)
2/2 Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients (Aesthetic Surgery Journal, 2021) (opens in new window)
PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color (Dermatologic Surgery, 2021) (opens in new window)
Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients (Aesthetic Surgery Journal, 2019) (opens in new window)
Phase III Study Results for Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects (Dermatologic Surgery, 2019) (opens in new window)

Contact Us

David K. Erickson
Vice President, Investor Relations

949.966.1798
david.erickson@evolus.com
IR@evolus.com

Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Evolus, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Evolus to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*



Unsubscribe

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT >
Evolus, Inc
  • Privacy Policy
  • Terms of Use
© Evolus, Inc. - All rights reserved
Powered By Q4 Inc. 5.90.0.6 (opens in new window)